Abstract
Statins are the cornerstone of lipid therapy because they have been proven beneficial in numerous outcome studies. Combinations of statins with omega-3-fatty acids or fibrates have shown no additional risk reduction, although subgroups may benefit from such combinations. Combinations of statins with either ezetimibe or niacin are currently investigated in large outcome trials. New compounds such as mipomersen (apoB antisense oligonucleotide), MTP inhibitors, and PCSK9 antibodies primarily decrease LDL-cholesterol but also reduce lipoprotein(a) to a varying degree. CETP inhibitors and apoA1 directed approaches primarily enhance reverse cholesterol transport but may also affect LDL-cholesterol concentration (CETP inhibitors). Although the lipid effects of these new compounds are promising only clinical studies will show which drugs will ultimately be beneficial to the patients.
